Lilly (Eli) (LLY) Q1 2026: Earnings & Growth Story
LLY · NYSE · Q1 2026 · 2026-07-23
Period ended 2026-03-31 · Based on the latest SEC filing
Top Surprise
Net income surged to $7.4 billion in Q1 2026, up 168% year-over-year.
Hidden Risk
Operating cash flow lagged significantly at $5.3 billion, despite a net income of $7.4 billion, suggesting potential future cash flow challenges.
Key Variable to Watch
Monitor Zepbound's sales performance as it remains pivotal for maintaining momentum in upcoming quarters.
Revenue
$19.8B
Net Income
$7.4B
Earnings Per Share
$8.26
Gross Margin
81.9%
Operating Cash Flow
$5.3B
Flash Briefing
⚡ Top Surprise: Net income surged to $7.4 billion in Q1 2026, up 168% year-over-year.
🚨 Hidden Risk: Operating cash flow lagged significantly at $5.3 billion, despite a net income of $7.4 billion, suggesting potential future cash flow challenges.
🔭 Key Variable: Monitor Zepbound's sales performance as it remains pivotal for maintaining momentum in upcoming quarters.
Company Growth Story
Eli Lilly's fiscal trajectory has dramatically shifted, reflected by a substantial top-line growth reported in Q1 2026, with revenue soaring 56% to $19.8 billion compared to the prior year.
This growth continues to be fueled by the successful launch and performance of Zepbound and Mounjaro, both critical to meeting evolving healthcare needs.
Growth in non-U.S.
markets has also seen impressive traction, primarily through a strategic expansion in emerging markets.
Notably, Zepbound's U.S.
revenue alone surged by 79%.
Despite these gains, the company faces headwinds from fluctuating pricing pressures and increased competition in the pharmaceutical sector.
The path ahead hinges on optimizing operational execution while navigating these complexities, placing a premium on robust managerial strategies.
Financial Health & Operating Reality
| Metric | Q1 2026 | Prior Year | Change |
|---|---|---|---|
| Revenue | $19.8B | $12.7B | +56% |
| Gross Margin | 81.9% | 82.5% | -0.6pp |
| Operating Income | N/A | N/A | N/A |
| Net Income | $7.4B | $2.8B | +168% |
| Diluted EPS | $8.26 | $3.06 | +170% |
| Operating Cash Flow | $5.3B | $1.7B | +218% |
Scenario Tree
| 🐂 Bull Case | 📊 Base Case | 🐻 Bear Case | |
|---|---|---|---|
| Key Assumption | Continued robust sales growth amid broader market demand. | Steady growth driven by existing product lines and pipeline. | Slower growth due to price pressures and market competition. |
| Validates when | New product launches exceed expectations. | Product line demand stabilizes. | Competitive pressures increase pricing instability. |
| Invalidates when | Competitors gain substantial market share. | Regulatory hurdles disrupt product pipeline. | Significant earnings decline amid operational inefficiency. |
| 12–36m Outlook | Projected revenue growth accelerated to 70%. | Revenue growth stabilizing at 15%. | Revenue declines as share prices and volume decrease significantly. |
Management Tone Analysis
-
Product Pipeline: Signal of confidence as management highlighted strategic advancements without hesitation.
-
Pricing Strategy: Cautious tone revealed concerns about market dynamics and pressures potentially in the coming quarters.
Cross-Validation
Web signals corroborate the official filing narrative, highlighting a sustained growth trend alongside strategic pipeline developments and competitive dynamics.